EX-FILING FEES 4 exhibit_107.htm EXHIBIT 107

Exhibit 107

EX-FILING FEES
 
Calculation of Filing Fee Tables
Form S-8
(Form Type)
RedHill Biopharma Ltd.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities and Carry Forward Securities
 
 
 
Security
Type
 
Security
Class
Title
 
Fee
Calculation
or Carry
Forward
Rule
 
 
Amount
Registered (2)
 
 
Proposed
Maximum
Offering
Price Per
Unit
 
 
Maximum
Aggregate
Offering
Price (3)
 
 
Fee
Rate
 
 
Amount of
Registration
Fee
 
 
 
 
                                                             
Fees to Be Paid
 
Equity
 
Ordinary Shares, par value NIS 0.01 per share (1)
 
457(h)
       
200,000,000
     
$0.0038
   
$
760,000
     
0.0001102
   
$
83.8
     
       
Total Offering Amounts
                         
$
760,000
                     
       
Total Fees Previously Paid
                                                   
       
Total Fee Offsets
                                                   
       
Net Fee Due
                                           $
83.8
     
                                                             

(1)
Deposited as American Depositary Shares (“ADSs”), evidenced by American Depositary Receipts, issuable upon deposit of the ordinary shares registered hereby, par value NIS 0.01 per share (“Ordinary Shares”), of Redhill Biopharma Ltd. (the “Company”) are registered on a separate registration statement on Form F-6 (File No. 333-268713). Each ADS represents four hundred (400) Ordinary Shares.
(2)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this registration statement shall also cover any additional Ordinary Shares that become issuable under the Redhill Biopharma Ltd. Amended and Restated Award Plan (2010), as amended by reason of any stock dividend, stock split, or other similar transaction.
(3)
Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act and based on the average of the high and low prices of the Company's ADSs reported on the NASDAQ Global Market on June 27, 2023.